Date from more than four Phase III clinical trials of AMAG Pharmaceuticals’ IV iron replacement therapy ferumoxytol have demonstrated positive efficacy and safety results. Aggregate data for three studies showed a significantly greater mean hemoglobin increase from the base line to the 35th day in patients who received ferumoxytol, as compared to those who received oral iron.